{"id":"W2994917610","doi":"10.1200/jco.19.01455","title":"NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":420,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval; Centre Hospitalier de l’Université de Montréal; McGill University","funders":"National Cancer Institute; American Society of Clinical Oncology; Amgen; Pfizer; Eli Lilly and Company; Genentech","keywords":"Trastuzumab; Medicine; Oncology; Internal medicine; Breast cancer; Hazard ratio; Cyclophosphamide; Docetaxel; Chemotherapy; Immunohistochemistry; Adjuvant; Cancer; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00722555,0.0003804981,0.006812479,0.0002391871,0.00007073997,0.00002858864,0.0002978554,0.0005492732,0.0006504876],"category_scores_gemma":[0.003057456,0.0001929514,0.0003261389,0.0003337946,0.001032243,0.0002051143,0.0000549136,0.002254274,0.000003207485],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009853957,"about_ca_system_score_gemma":0.01196866,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001440587,"about_ca_topic_score_gemma":0.01289879,"domain_scores_codex":[0.9932959,0.00172722,0.003084816,0.0005645449,0.0006901944,0.0006373273],"domain_scores_gemma":[0.978784,0.01636332,0.003067304,0.0002739721,0.0008435893,0.0006677805],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8663756,0.003339153,0.02394331,0.0001120742,0.001548051,0.0003793761,0.0008076338,0.00003026063,0.00006156218,0.000004762587,0.004975353,0.09842283],"study_design_scores_gemma":[0.8748463,0.1062088,0.005531505,0.0007299162,0.000787838,0.0008107586,0.000830513,0.0007684319,0.0001507918,0.00004537087,0.009049068,0.000240659],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9792491,0.0001507819,0.0003948582,0.01383623,0.0006837374,0.005272272,0.00007823658,0.00001385877,0.000320934],"genre_scores_gemma":[0.9853699,0.003677509,0.004308513,0.003983763,0.001433241,0.0003539623,0.000007446339,0.0000786366,0.0007870182],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1028696,"threshold_uncertainty_score":0.9936326,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1163470475283686,"score_gpt":0.5119909698977256,"score_spread":0.3956439223693571,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}